• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Rein Therapeutics Inc.

    6/8/26 9:17:41 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNTX alert in real time by email
    DEFA14A 1 rntx-defa14a-2026.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12

     

    REIN THERAPEUTICS, INC.

    (Name of Registrant as Specified in Its Charter)

     

     

     

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 2(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

     

     

     

     

     

     


     

     

    img142772922_0.jpg

    Online Go to https://www.envisionreports.com/RNTX or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice Important Notice Regarding the Availability of Proxy Materials for the Rein Therapeutics, Inc. 2026 Annual Meeting of Stockholders to be held on July 20, 2026 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual meeting of stockholders are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2026 Proxy Statement and Annual Report are available at: Easy Online Access — View your proxy materials and vote. Step 1: Go to https://www.envisionreports.com/RNTX. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before July 1, 2026 to facilitate timely delivery. 2NOT

     


     

     

    img142772922_1.jpg

    Stockholder Meeting Notice Rein Therapeutics’ 2026 Annual Meeting of Stockholders will be held on July 20, 2026 online at meetnow.global/MM4MRP6 at 9:00AM ET. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR the nominees listed and FOR Proposals 2, 3 and 4: 1. Election of Two Class III Directors: 01 – Reinhard J. Ambros, Ph.D. 02 - Josef H. von Rickenbach 2. Approval to Increase Authorized Shares of Common Stock 3. Ratification of Appointment of CBIZ CPAs P.C. as Independent Registered Public Accounting Firm 4. Advisory Vote to Approve Named Executive Officer Compensation PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to https://www.envisionreports.com/RNTX. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to investorvote@computershare.com with “Proxy Materials Rein Therapeutics” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by July 1, 2026.

     


    Get the next $RNTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNTX

    DatePrice TargetRatingAnalyst
    9/22/2025$10.00Buy
    H.C. Wainwright
    1/28/2025$8.00Buy
    Rodman & Renshaw
    More analyst ratings

    $RNTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

    Total gross proceeds increased to $57.5 millionOffering consisted solely of common stockProceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters' over-allotment option. The financing included new and existing healthcare-focused investors

    5/18/26 8:00:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

    AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of $50 million, prior to deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 7.5M shares of common stock at the public offering

    4/30/26 8:00:00 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

    Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near termEnrollment initiated in March 2026, with patients being added on a regular basisClinical trial sites active in the United States, Australia, and Poland, with additional countries expected to open in the near term AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2

    4/29/26 8:00:00 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Von Rickenbach Josef H bought $49,561 worth of Common stock (47,060 units at $1.05), increasing direct ownership by 305% to 62,514 units (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    5/28/26 8:15:59 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Windsor James Brian bought $25,000 worth of Common stock (25,000 units at $1.00), increasing direct ownership by 1,222% to 27,046 units (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    5/13/26 8:47:13 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Voss Capital, Lp bought $127,593 worth of shares (104,183 units at $1.22) (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    11/18/25 5:30:44 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Von Rickenbach Josef H bought $49,561 worth of Common stock (47,060 units at $1.05), increasing direct ownership by 305% to 62,514 units (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    5/28/26 8:15:59 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Windsor James Brian bought $25,000 worth of Common stock (25,000 units at $1.00), increasing direct ownership by 1,222% to 27,046 units (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    5/13/26 8:47:13 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Voss Capital, Lp bought $127,593 worth of shares (104,183 units at $1.22) (SEC Form 4)

    4 - Rein Therapeutics, Inc. (0001420565) (Issuer)

    11/18/25 5:30:44 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Rein Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $10.00

    9/22/25 8:32:15 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Rein Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00

    1/28/25 7:16:42 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNTX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Rein Therapeutics Inc.

    DEFA14A - Rein Therapeutics, Inc. (0001420565) (Filer)

    6/8/26 9:17:41 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Rein Therapeutics Inc.

    DEF 14A - Rein Therapeutics, Inc. (0001420565) (Filer)

    6/8/26 9:17:30 AM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Rein Therapeutics Inc.

    PRE 14A - Rein Therapeutics, Inc. (0001420565) (Filer)

    5/28/26 4:43:15 PM ET
    $RNTX
    Biotechnology: Pharmaceutical Preparations
    Health Care